Irit Gliko-Kabir
Chief Tech/Sci/R&D Officer bij BIOLINERX LTD.
Profiel
Irit Gliko-Kabir is currently working as the Vice President-Clinical Operations at BioLineRx Ltd.
She started this position in 2021.
Previously, she worked as the Senior Director-Clinical Development at Bioblast Pharma Ltd.
Dr. Gliko-Kabir has an educational background, having obtained undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Actieve functies van Irit Gliko-Kabir
Bedrijven | Functie | Begin |
---|---|---|
BIOLINERX LTD. | Chief Tech/Sci/R&D Officer | 01-09-2017 |
Eerdere bekende functies van Irit Gliko-Kabir
Bedrijven | Functie | Einde |
---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |